Sabine D. Brookman-May, Professor of Urology at Munich University and Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post by Tyra Biosciences on X, adding:
“So important to get the right treatments developed for upper tract disease UTUC.
Looking forward to seeing more trials in this indication as we need an organ sparing approach here.
Dabogratinib might offer a great option to treat these patients given the high rate of FGFR3 alterations in UTUC + the improved safety profile compared to unselective FGFR inhibitors.”
Quoting Tyra Biosciences‘s post:
“Last week at EAU 2026, our team connected with industry peers across the Urologic Oncology community and engaged in discussions shaping the future of patient care. We look forward to continued collaboration looking forward.”
Other articles about Urologic Oncology on OncoDaily.